XTL BiopharmaceuticalsXTLB
13F holders, Q2 2025 (June 30)4holders
1new positions
1sold out
$1.14avg. 13F price*
At the end of Q2 2025, 4 institutions reported holding XTL Biopharmaceuticals Ltd. (XTLB) in their 13F filings, unchanged from Q1 2025. 1 opened new positions and 1 sold out. The largest holders were Noked Israel Ltd ($227K), Rhumbline Advisers ($20K) and Morgan Stanley ($13K).
- Company
- XTL Biopharmaceuticals Ltd.
- CUSIP
- 98386D307
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $2K |
| Exits | 1 | $31K |
All 13F filers, Q1 2025 → Q2 2025: 7,643 shares bought and 27,451 shares sold, net −19,808 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Noked Israel Ltd | 0.04% | No change | 198,888 | $227K |
| Rhumbline Advisers | 0.00% | Add +57.6% | 17,261 | $20K |
| Morgan Stanley | 0.00% | Reduce -16.9% | 11,011 | $13K |
| UBS Group AG | 0.00% | New | 1,336 | $2K |
"% of holder's portfolio" is XTLB's weight in each manager's 13F, not the share of XTL Biopharmaceuticals Ltd. the manager owns.